Here are three things to know.
1. Glatopa, manufactured by Novartis’ subsidiary Sandoz, is intended for patients with relapsing forms of multiple sclerosis. The drug is administered as an injection three times a week.
2. Sandoz earned FDA approval for a smaller dosage of Glatopa in 2015. Contamination issues at a production plant delayed regulatory approval of the new dosage form until this month.
3. Glatopa represents the second generic version of Teva’s brand-name drug to enter the market. Mylan launched its version in 2017.
More articles on supply chain:
FDA OKs Novartis’ generic version of Teva’s MS drug: 3 things to know
Walgreens is reportedly in talks to purchase AmerisourceBergen: 7 things to know
Philips recalls HeartStart MRx Defibrillator: 3 things to know
